MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Large Increase in Short Interest

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIAGet Free Report) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,010,000 shares, a growth of 28.6% from the April 15th total of 785,200 shares. Currently, 6.3% of the shares of the company are sold short. Based on an average daily trading volume, of 355,400 shares, the days-to-cover ratio is currently 2.8 days.

Insiders Place Their Bets

In other MAIA Biotechnology news, Director Ngar Yee Louie purchased 19,665 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The shares were bought at an average cost of $2.03 per share, for a total transaction of $39,919.95. Following the purchase, the director now owns 1,167,189 shares of the company’s stock, valued at approximately $2,369,393.67. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Ngar Yee Louie acquired 19,665 shares of the firm’s stock in a transaction that occurred on Thursday, April 25th. The shares were bought at an average cost of $2.03 per share, for a total transaction of $39,919.95. Following the purchase, the director now owns 1,167,189 shares in the company, valued at approximately $2,369,393.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stan Smith bought 170,940 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was bought at an average price of $1.17 per share, with a total value of $199,999.80. Following the purchase, the director now owns 857,568 shares in the company, valued at $1,003,354.56. The disclosure for this purchase can be found here. Company insiders own 36.98% of the company’s stock.

MAIA Biotechnology Price Performance

NYSEAMERICAN MAIA traded up $0.03 on Wednesday, hitting $2.87. The stock had a trading volume of 87,368 shares, compared to its average volume of 380,657. The stock has a market capitalization of $59.06 million, a PE ratio of -1.91 and a beta of 0.04. MAIA Biotechnology has a 52-week low of $0.82 and a 52-week high of $3.59.

MAIA Biotechnology (NYSEAMERICAN:MAIAGet Free Report) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). On average, research analysts anticipate that MAIA Biotechnology will post -1.25 EPS for the current year.

About MAIA Biotechnology

(Get Free Report)

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

Featured Stories

Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.